1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Somatostatin Analogs 1.2.3 Targeted Therapy 1.2.4 Chemotherapy 1.3 Market by Application 1.3.1 Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Oncology Centers 1.3.5 Ambulatory Surgical Centers 1.3.6 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Neuroendocrine Carcinoma Treatment Market Perspective (2017-2028) 2.2 Neuroendocrine Carcinoma Treatment Growth Trends by Region 2.2.1 Neuroendocrine Carcinoma Treatment Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Neuroendocrine Carcinoma Treatment Historic Market Size by Region (2017-2022) 2.2.3 Neuroendocrine Carcinoma Treatment Forecasted Market Size by Region (2023-2028) 2.3 Neuroendocrine Carcinoma Treatment Market Dynamics 2.3.1 Neuroendocrine Carcinoma Treatment Industry Trends 2.3.2 Neuroendocrine Carcinoma Treatment Market Drivers 2.3.3 Neuroendocrine Carcinoma Treatment Market Challenges 2.3.4 Neuroendocrine Carcinoma Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue 3.1.1 Global Top Neuroendocrine Carcinoma Treatment Players by Revenue (2017-2022) 3.1.2 Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Players (2017-2022) 3.2 Global Neuroendocrine Carcinoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Treatment Revenue 3.4 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio 3.4.1 Global Neuroendocrine Carcinoma Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Treatment Revenue in 2021 3.5 Neuroendocrine Carcinoma Treatment Key Players Head office and Area Served 3.6 Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service 3.7 Date of Enter into Neuroendocrine Carcinoma Treatment Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Neuroendocrine Carcinoma Treatment Breakdown Data by Type 4.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Type (2017-2022) 4.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2023-2028) 5 Neuroendocrine Carcinoma Treatment Breakdown Data by Application 5.1 Global Neuroendocrine Carcinoma Treatment Historic Market Size by Application (2017-2022) 5.2 Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Neuroendocrine Carcinoma Treatment Market Size (2017-2028) 6.2 North America Neuroendocrine Carcinoma Treatment Market Size by Type 6.2.1 North America Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) 6.2.2 North America Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) 6.2.3 North America Neuroendocrine Carcinoma Treatment Market Share by Type (2017-2028) 6.3 North America Neuroendocrine Carcinoma Treatment Market Size by Application 6.3.1 North America Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) 6.3.2 North America Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) 6.3.3 North America Neuroendocrine Carcinoma Treatment Market Share by Application (2017-2028) 6.4 North America Neuroendocrine Carcinoma Treatment Market Size by Country 6.4.1 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) 6.4.2 North America Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Neuroendocrine Carcinoma Treatment Market Size (2017-2028) 7.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Type 7.2.1 Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) 7.2.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) 7.2.3 Europe Neuroendocrine Carcinoma Treatment Market Share by Type (2017-2028) 7.3 Europe Neuroendocrine Carcinoma Treatment Market Size by Application 7.3.1 Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) 7.3.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) 7.3.3 Europe Neuroendocrine Carcinoma Treatment Market Share by Application (2017-2028) 7.4 Europe Neuroendocrine Carcinoma Treatment Market Size by Country 7.4.1 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) 7.4.2 Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size (2017-2028) 8.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type 8.2.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Share by Type (2017-2028) 8.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application 8.3.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Share by Application (2017-2028) 8.4 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region 8.4.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Neuroendocrine Carcinoma Treatment Market Size (2017-2028) 9.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Type 9.2.1 Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) 9.2.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) 9.2.3 Latin America Neuroendocrine Carcinoma Treatment Market Share by Type (2017-2028) 9.3 Latin America Neuroendocrine Carcinoma Treatment Market Size by Application 9.3.1 Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) 9.3.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) 9.3.3 Latin America Neuroendocrine Carcinoma Treatment Market Share by Application (2017-2028) 9.4 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country 9.4.1 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) 9.4.2 Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size (2017-2028) 10.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type 10.2.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Share by Type (2017-2028) 10.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application 10.3.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Share by Application (2017-2028) 10.4 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country 10.4.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Pfizer 11.1.1 Pfizer Company Details 11.1.2 Pfizer Business Overview 11.1.3 Pfizer Neuroendocrine Carcinoma Treatment Introduction 11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.1.5 Pfizer Recent Developments 11.2 Novartis 11.2.1 Novartis Company Details 11.2.2 Novartis Business Overview 11.2.3 Novartis Neuroendocrine Carcinoma Treatment Introduction 11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.2.5 Novartis Recent Developments 11.3 Chiasma, Inc. 11.3.1 Chiasma, Inc. Company Details 11.3.2 Chiasma, Inc. Business Overview 11.3.3 Chiasma, Inc. Neuroendocrine Carcinoma Treatment Introduction 11.3.4 Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.3.5 Chiasma, Inc. Recent Developments 11.4 Ipsen 11.4.1 Ipsen Company Details 11.4.2 Ipsen Business Overview 11.4.3 Ipsen Neuroendocrine Carcinoma Treatment Introduction 11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.4.5 Ipsen Recent Developments 11.5 AbbVie 11.5.1 AbbVie Company Details 11.5.2 AbbVie Business Overview 11.5.3 AbbVie Neuroendocrine Carcinoma Treatment Introduction 11.5.4 AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.5.5 AbbVie Recent Developments 11.6 Bausch Health 11.6.1 Bausch Health Company Details 11.6.2 Bausch Health Business Overview 11.6.3 Bausch Health Neuroendocrine Carcinoma Treatment Introduction 11.6.4 Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.6.5 Bausch Health Recent Developments 11.7 Jubilant 11.7.1 Jubilant Company Details 11.7.2 Jubilant Business Overview 11.7.3 Jubilant Neuroendocrine Carcinoma Treatment Introduction 11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.7.5 Jubilant Recent Developments 11.8 Teva Pharmaceutical Industries Ltd. 11.8.1 Teva Pharmaceutical Industries Ltd. Company Details 11.8.2 Teva Pharmaceutical Industries Ltd. Business Overview 11.8.3 Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Introduction 11.8.4 Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.8.5 Teva Pharmaceutical Industries Ltd. Recent Developments 11.9 Roche 11.9.1 Roche Company Details 11.9.2 Roche Business Overview 11.9.3 Roche Neuroendocrine Carcinoma Treatment Introduction 11.9.4 Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.9.5 Roche Recent Developments 11.10 Mateon 11.10.1 Mateon Company Details 11.10.2 Mateon Business Overview 11.10.3 Mateon Neuroendocrine Carcinoma Treatment Introduction 11.10.4 Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) 11.10.5 Mateon Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer

List of Tables Table 1. Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Somatostatin Analogs Table 3. Key Players of Targeted Therapy Table 4. Key Players of Chemotherapy Table 5. Global Neuroendocrine Carcinoma Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 6. Global Neuroendocrine Carcinoma Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Neuroendocrine Carcinoma Treatment Market Size by Region (2017-2022) & (US$ Million) Table 8. Global Neuroendocrine Carcinoma Treatment Market Share by Region (2017-2022) Table 9. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 10. Global Neuroendocrine Carcinoma Treatment Market Share by Region (2023-2028) Table 11. Neuroendocrine Carcinoma Treatment Market Trends Table 12. Neuroendocrine Carcinoma Treatment Market Drivers Table 13. Neuroendocrine Carcinoma Treatment Market Challenges Table 14. Neuroendocrine Carcinoma Treatment Market Restraints Table 15. Global Neuroendocrine Carcinoma Treatment Revenue by Players (2017-2022) & (US$ Million) Table 16. Global Neuroendocrine Carcinoma Treatment Revenue Share by Players (2017-2022) Table 17. Global Top Neuroendocrine Carcinoma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2021) Table 18. Ranking of Global Top Neuroendocrine Carcinoma Treatment Companies by Revenue (US$ Million) in 2021 Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Treatment Revenue (CR5 and HHI) & (2017-2022) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Neuroendocrine Carcinoma Treatment Product Solution and Service Table 22. Date of Enter into Neuroendocrine Carcinoma Treatment Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) & (US$ Million) Table 25. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2017-2022) Table 26. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 27. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type (2023-2028) Table 28. Global Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million) Table 29. Global Neuroendocrine Carcinoma Treatment Revenue Share by Application (2017-2022) Table 30. Global Neuroendocrine Carcinoma Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 31. Global Neuroendocrine Carcinoma Treatment Revenue Share by Application (2023-2028) Table 32. North America Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) & (US$ Million) Table 33. North America Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) & (US$ Million) Table 34. North America Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million) Table 35. North America Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million) Table 36. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million) Table 37. North America Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million) Table 38. Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) & (US$ Million) Table 39. Europe Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) & (US$ Million) Table 40. Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million) Table 41. Europe Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million) Table 42. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million) Table 43. Europe Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million) Table 44. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) & (US$ Million) Table 45. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) & (US$ Million) Table 46. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million) Table 47. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million) Table 48. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2017-2022) & (US$ Million) Table 49. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size by Region (2023-2028) & (US$ Million) Table 50. Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) & (US$ Million) Table 51. Latin America Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) & (US$ Million) Table 52. Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million) Table 53. Latin America Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million) Table 54. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million) Table 55. Latin America Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million) Table 56. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2017-2022) & (US$ Million) Table 57. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size by Type (2023-2028) & (US$ Million) Table 58. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2017-2022) & (US$ Million) Table 59. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size by Application (2023-2028) & (US$ Million) Table 60. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2017-2022) & (US$ Million) Table 61. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size by Country (2023-2028) & (US$ Million) Table 62. Pfizer Company Details Table 63. Pfizer Business Overview Table 64. Pfizer Neuroendocrine Carcinoma Treatment Product Table 65. Pfizer Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 66. Pfizer Recent Developments Table 67. Novartis Company Details Table 68. Novartis Business Overview Table 69. Novartis Neuroendocrine Carcinoma Treatment Product Table 70. Novartis Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 71. Novartis Recent Developments Table 72. Chiasma, Inc. Company Details Table 73. Chiasma, Inc. Business Overview Table 74. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Product Table 75. Chiasma, Inc. Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 76. Chiasma, Inc. Recent Developments Table 77. Ipsen Company Details Table 78. Ipsen Business Overview Table 79. Ipsen Neuroendocrine Carcinoma Treatment Product Table 80. Ipsen Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 81. Ipsen Recent Developments Table 82. AbbVie Company Details Table 83. AbbVie Business Overview Table 84. AbbVie Neuroendocrine Carcinoma Treatment Product Table 85. AbbVie Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 86. AbbVie Recent Developments Table 87. Bausch Health Company Details Table 88. Bausch Health Business Overview Table 89. Bausch Health Neuroendocrine Carcinoma Treatment Product Table 90. Bausch Health Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 91. Bausch Health Recent Developments Table 92. Jubilant Company Details Table 93. Jubilant Business Overview Table 94. Jubilant Neuroendocrine Carcinoma Treatment Product Table 95. Jubilant Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 96. Jubilant Recent Developments Table 97. Teva Pharmaceutical Industries Ltd. Company Details Table 98. Teva Pharmaceutical Industries Ltd. Business Overview Table 99. Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Product Table 100. Teva Pharmaceutical Industries Ltd. Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 101. Teva Pharmaceutical Industries Ltd. Recent Developments Table 102. Roche Company Details Table 103. Roche Business Overview Table 104. Roche Neuroendocrine Carcinoma Treatment Product Table 105. Roche Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 106. Roche Recent Developments Table 107. Mateon Company Details Table 108. Mateon Business Overview Table 109. Mateon Neuroendocrine Carcinoma Treatment Product Table 110. Mateon Revenue in Neuroendocrine Carcinoma Treatment Business (2017-2022) & (US$ Million) Table 111. Mateon Recent Developments Table 112. Research Programs/Design for This Report Table 113. Key Data Information from Secondary Sources Table 114. Key Data Information from Primary Sources List of Figures Figure 1. Global Neuroendocrine Carcinoma Treatment Market Share by Type: 2021 VS 2028 Figure 2. Somatostatin Analogs Features Figure 3. Targeted Therapy Features Figure 4. Chemotherapy Features Figure 5. Global Neuroendocrine Carcinoma Treatment Market Share by Application: 2021 VS 2028 Figure 6. Hospitals Case Studies Figure 7. Clinics Case Studies Figure 8. Oncology Centers Case Studies Figure 9. Ambulatory Surgical Centers Case Studies Figure 10. Others Case Studies Figure 11. Neuroendocrine Carcinoma Treatment Report Years Considered Figure 12. Global Neuroendocrine Carcinoma Treatment Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 13. Global Neuroendocrine Carcinoma Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 14. Global Neuroendocrine Carcinoma Treatment Market Share by Region: 2021 VS 2028 Figure 15. Global Neuroendocrine Carcinoma Treatment Market Share by Players in 2021 Figure 16. Global Top Neuroendocrine Carcinoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Treatment as of 2021) Figure 17. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Treatment Revenue in 2021 Figure 18. North America Neuroendocrine Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 19. North America Neuroendocrine Carcinoma Treatment Market Size Market Share by Type (2017-2028) Figure 20. North America Neuroendocrine Carcinoma Treatment Market Size Market Share by Application (2017-2028) Figure 21. North America Neuroendocrine Carcinoma Treatment Market Size Share by Country (2017-2028) Figure 22. United States Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Canada Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Europe Neuroendocrine Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 25. Europe Neuroendocrine Carcinoma Treatment Market Size Market Share by Type (2017-2028) Figure 26. Europe Neuroendocrine Carcinoma Treatment Market Size Market Share by Application (2017-2028) Figure 27. Europe Neuroendocrine Carcinoma Treatment Market Size Share by Country (2017-2028) Figure 28. Germany Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. France Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. U.K. Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Italy Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Russia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Nordic Countries Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Asia-Pacific Neuroendocrine Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 35. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size Market Share by Type (2017-2028) Figure 36. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size Market Share by Application (2017-2028) Figure 37. Asia Pacific Neuroendocrine Carcinoma Treatment Market Size Share by Region (2017-2028) Figure 38. China Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Japan Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. South Korea Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Southeast Asia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. India Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Australia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 44. Latin America Neuroendocrine Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 45. Latin America Neuroendocrine Carcinoma Treatment Market Size Market Share by Type (2017-2028) Figure 46. Latin America Neuroendocrine Carcinoma Treatment Market Size Market Share by Application (2017-2028) Figure 47. Latin America Neuroendocrine Carcinoma Treatment Market Size Share by Country (2017-2028) Figure 48. Mexico Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 49. Brazil Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 50. Middle East & Africa Neuroendocrine Carcinoma Treatment Market Size YoY (2017-2028) & (US$ Million) Figure 51. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size Market Share by Type (2017-2028) Figure 52. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size Market Share by Application (2017-2028) Figure 53. Middle East and Africa Neuroendocrine Carcinoma Treatment Market Size Share by Country (2017-2028) Figure 54. Turkey Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 55. Saudi Arabia Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 56. UAE Neuroendocrine Carcinoma Treatment Market Size YoY Growth (2017-2028) & (US$ Million) Figure 57. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 58. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 59. Chiasma, Inc. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 60. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 61. AbbVie Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 62. Bausch Health Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 63. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 64. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 65. Roche Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 66. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Treatment Business (2017-2022) Figure 67. Bottom-up and Top-down Approaches for This Report Figure 68. Data Triangulation Figure 69. Key Executives Interviewed

Pfizer Novartis Chiasma, Inc. Ipsen AbbVie Bausch Health Jubilant Teva Pharmaceutical Industries Ltd. Roche Mateon